🇺🇸
~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial…
Source: prnewswire
Country: United States